In Veritas Medical Stock Current Valuation
| IVME Stock | USD 0.0001 0.00 0.00% |
Valuation analysis of In Veritas Medical helps investors to measure In Veritas' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of December 18, 2024, Enterprise Value Over EBITDA is expected to decline to -1.38. In addition to that, Enterprise Value Multiple is expected to decline to -1.38. Fundamental drivers impacting In Veritas' valuation include:
Enterprise Value 8.6 K | Enterprise Value Ebitda (2.17) | Price Sales 0.1429 |
Overvalued
Today
Please note that In Veritas' price fluctuation is very steady at this time. Calculation of the real value of In Veritas Medical is based on 3 months time horizon. Increasing In Veritas' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the IVME stock is determined by what a typical buyer is willing to pay for full or partial control of In Veritas Medical. Since In Veritas is currently traded on the exchange, buyers and sellers on that exchange determine the market value of IVME Stock. However, In Veritas' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 |
The real value of IVME Stock, also known as its intrinsic value, is the underlying worth of In Veritas Medical Company, which is reflected in its stock price. It is based on In Veritas' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of In Veritas' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of In Veritas Medical helps investors to forecast how IVME stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of In Veritas more accurately as focusing exclusively on In Veritas' fundamentals will not take into account other important factors: In Veritas Medical Company Current Valuation Analysis
In Veritas' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current In Veritas Current Valuation | 8.6 K |
Most of In Veritas' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, In Veritas Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
IVME Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for In Veritas is extremely important. It helps to project a fair market value of IVME Stock properly, considering its historical fundamentals such as Current Valuation. Since In Veritas' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of In Veritas' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of In Veritas' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, In Veritas Medical has a Current Valuation of 8.6 K. This is 100.0% lower than that of the Capital Markets sector and significantly higher than that of the Financials industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
IVME Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses In Veritas' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of In Veritas could also be used in its relative valuation, which is a method of valuing In Veritas by comparing valuation metrics of similar companies.In Veritas is currently under evaluation in current valuation category among its peers.
IVME Fundamentals
| Return On Asset | -6.48 | ||||
| Current Valuation | 8.6 K | ||||
| Shares Outstanding | 86.05 M | ||||
| Price To Earning | (0.01) X | ||||
| Price To Sales | 0.14 X | ||||
| EBITDA | (2.07 M) | ||||
| Net Income | (3.67 M) | ||||
| Total Debt | 1.21 M | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (727.72 K) | ||||
| Earnings Per Share | (0.01) X | ||||
| Beta | 9.03 | ||||
| Market Capitalization | 8.61 K | ||||
| Total Asset | 111.95 K | ||||
| Net Asset | 111.95 K |
About In Veritas Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze In Veritas Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of In Veritas using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of In Veritas Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether In Veritas Medical is a strong investment it is important to analyze In Veritas' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact In Veritas' future performance. For an informed investment choice regarding IVME Stock, refer to the following important reports:Check out In Veritas Piotroski F Score and In Veritas Altman Z Score analysis. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of In Veritas. If investors know IVME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about In Veritas listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Return On Assets (6.48) |
The market value of In Veritas Medical is measured differently than its book value, which is the value of IVME that is recorded on the company's balance sheet. Investors also form their own opinion of In Veritas' value that differs from its market value or its book value, called intrinsic value, which is In Veritas' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because In Veritas' market value can be influenced by many factors that don't directly affect In Veritas' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between In Veritas' value and its price as these two are different measures arrived at by different means. Investors typically determine if In Veritas is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, In Veritas' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.